株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のナノ粒子ドラッグデリバリー市場、投与量、価格および臨床パイプラインの展望

Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024

発行 KuicK Research 商品コード 624706
出版日 ページ情報 英文 480 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界のナノ粒子ドラッグデリバリー市場、投与量、価格および臨床パイプラインの展望 Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024
出版日: 2018年04月10日 ページ情報: 英文 480 Pages
概要

当レポートでは、世界のナノ粒子ドラッグデリバリー市場について取り上げ、現在の市場規模、動向、機会、および市場ダイナミクスについて詳細に分析しており、先発医薬品とナノ粒子処方薬の価格、投与量、および治療費の比較分析、地域的な市場機会、および世界市場の予測などを提供しています。

第1章 ナノ粒子:ドラッグデリバリー手法の革命

第2章 ナノ粒子ドラッグデリバリーのニーズ

第3章 従来のドラッグデリバリーに勝るナノ粒子をベースとしたドラッグデリバリーの優位性

第4章 癌治療におけるナノ粒子ドラッグデリバリーの重要性

第5章 ナノ粒子ドラッグデリバリーの既存技術

  • ナノ結晶
  • リポソーム
  • デンドリマー
  • ミセル系ドラッグデリバリー

第6章 近い将来のナノ粒子ドラッグデリバリー技術

  • ポリマーナノ粒子
  • 金属系ナノ粒子 (金、酸化鉄)
  • フラーレン・カーボンナノチューブ
  • 量子ドットデリバリー

第7章 世界のナノ粒子医薬品市場概要

  • 現在の市況
  • 世界のナノ粒子医薬品臨床パイプライン概要

第8章 市販ナノ粒子治療薬の価格・投与量分析

  • リポソーマルドキソルビシン
  • アムホテリシン
  • パクリタキセル (タキソール、Onxal)
  • シロリムス (ラパミューン)
  • イメンド (アプレピタントナノ結晶)
  • Megace ES (Enhanced Stability)
  • エストラジオールトピカルエマルジョン (Estrasorb)
  • その他のナノ粒子医薬品製剤

第9章 ナノ粒子ドラッグデリバリー:市場動向・特許分布分析

  • ナノ粒子ドラッグデリバリーにおける特許出願状況
  • 特許分布:ナノマテリアル種類別
  • 特許分布:刺激剤別
  • 特許分布:投与経路・ドラッグデリバリー形態別

第10章 ナノ粒子ドラッグデリバリー市場の促進要因

  • 疾患の罹患率の増加・より良い治療に対するニーズ
  • 従来型治療薬よりも優れた信頼性・安全性
  • R&Dの進歩
  • 有望な投資・市場潜在性
  • 革新的・優れた技術の急速な進歩

第11章 ナノ粒子ドラッグデリバリーセグメントの課題

  • 極めて高額な技術・ナノ粒子製品
  • ナノ粒子ドラッグデリバリーに関連した科学的・技術的な制限
  • 地域的な制限・低い市場浸透
  • 従来型ドラッグデリバリーセグメントの優位性

第12章 世界のナノ粒子ドラッグデリバリー市場の将来予測・市場分析

第13章 世界のナノ粒子医薬品臨床パイプライン:企業・適応症・位相

  • 未確認
  • 研究
  • 前臨床
  • 臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズII/III
  • フェーズIII
  • 登録前
  • 登録済み

第14章 市販ナノ粒子医薬品の臨床考察:企業・適応症

  • Rilpivirine (Edurant)
  • Albumin-Bound Paclitaxel (Abraxane, Coraxane & Coroxane)
  • Meloxicam (VIVLODEX)
  • Ferumoxytol (Feraheme & Rienso)
  • Paclitaxel Liposomal - Sun Pharma Advanced Research Company
  • Fenofibrate (Lipanthyl & TriCor)
  • Doxorubicin Liposomal (Caelyx & Doxil)
  • Vincristine Liposomal (Marqibo)
  • Fenofibrate (Triglide)
  • Rexin-G
  • Estradiol Topical (Estrasorb)
  • Glycyrrhiza/Phosphatidylcholine (Phosphogliv)
  • Paclitaxel Nanoparticle (Nanoxel)

第15章 競合情勢

  • Abraxis BioScience
  • Access Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • Arrowhead Research
  • BIND Therapeutics
  • Cadila Healthcare
  • Celegen Corporation
  • Celsion Corporation
  • Genzyme Corporation
  • Merck
  • NanoCarrier
  • 日本化薬
  • Nanobiotix
  • Novavax
  • Pfizer
  • Roche
  • Samyang
  • Sanofi
  • 武田薬品工業
目次

“Global Nanoparticle Drug Delivery Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights:

  • Nanoparticle Drug Market: US$ 200 Billion Opportunity By 2024
  • Global Pipeline For Nanoparticle Drug: 231 Drugs
  • Drugs In & Above Phase II Trials: 33 Drugs
  • Marketed Nanoparticle Drugs: 13 Drugs
  • Dosage, Price & Patent Analysis Of Key Drugs
  • Upcoming Nanoparticle Drug Delivery Techniques
  • Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase

Drug delivery plays a significant role in determining the therapeutic outcome of a treatment. The limitations of conventional drug delivery system such as low bioavailability of therapeutics, poor patient compliance and fluctuation in concentration has led to a dire need for the development of new, better and safer delivery method with enhanced therapeutic outcome and safety.

The practice of drug delivery has changed dramatically in the past few decades with substantial changes being anticipated in the future. An emerging method that clearly stands out is the use of nanotechnology in drug delivery which utilizes specially designed nanoparticles to enhance drug delivery more effectively and precisely with additional advantages such as longer circulation delivery, longer half-lives, better bioavailability, improved pharmacokinetics and reduced side effects.

Additionally, nanoparticles also have the ability to transport drug molecules across the blood brain barrier which can be exploited to develop revolutionizing therapeutics for clinical conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia and depression. It has also raised hope in complex disease like brain tumor - which is currently impossible to treat with conventional drug delivery methods.

An insight into the market trends shows that the ability of nanoparticles to enhance therapeutic outcome by a significant margin has led pharmaceutical companies to develop nanoparticle formulation of popular drugs like Megace ES(Enhanced Stability), Estrasorb (estradiol topical emulsion)and Triglide(Nanocrystal formulation of Tricor). Nanoparticle formulations of popular cancer therapeutics like Doxorubicin and Taxol has also been well received in the cancer therapeutic segment due to longer half-lives and reduced side effects.

Advancement in nanotechnology has resulted in the entry of many types of nanoparticles in the market. Nanocrystal and liposomes are currently the most popular nanoparticles in use, followed by micelles and dendrimers. Nanocrystal, liposomal and micelle formulations of therapeutics are being developed and marketed which is bound to increase the market size in the future.

Geographical Analysis of the Nanoparticle drug delivery method projects the increasing dominance of US with more than 40% of the global market, followed by Europe. However, the market size is anticipated to increase in the Asia Pacific and Latin American region during the forecast period due to multiple growth factors supporting the analysis, such as increase in patient base and the rising interest of key players like Johnson & Johnson and Novartis in the region.

KuicK Research Estimates the Global nanoparticle drug market to reach over US$ 200 Billion by 2024 at a CAGR of 10%. Growth promoting factors like increase in global prevalence of various clinical indications like cancer, diabetes and rheumatoid arthritis are bound to fuel the market growth with oncology being the dominant segment. The increasing demand for effective treatment methods to provide for the rising pool of patients are expected to help the segment retain dominance over the report's forecast period as well.

The nanoparticles drug delivery market however faces some major challenges that are anticipated to hamper with its future growth. High demand of investments, scientific and technical limitations and overcrowding of vendors and marketing challenges such as exorbitant pricing of therapeutics, limited market penetration and low awareness are hurdles that need to be taken care of to enhance the potential of nanoparticle drug delivery segment.

KuicK Research report on global nanoparticle drug delivery market provides an in-depth analysis of the market with special emphasis on the Global market size, current market trends, dynamics and other factors that might have an impact on the market. Comparative price, dosage and therapy cost analysis of Original drugs with Nanoparticle formulations analyses the promising potential of Nanoparticle drug delivery, ultimately proving its superiority. KuicK Research analysis is based on extensive research from both primary and secondary sources, highlighting the market opportunities regionally and ensuring an optimistic future forecast of the global nanoparticles drug delivery market.

Table of Contents

1. Nanoparticles - Revolutionizing Drug Delivery Method

  • 1.1. Prologue to Targeted Drug Delivery by Nanoparticles
  • 1.2. Nanoparticle Drug Delivery -Enhancing the Efficacy of Therapeutics by Nanotechnology

2. Need for Nanoparticle Drug Delivery

  • 2.1. Limitations of Traditional Drug Delivery Techniques
  • 2.2. Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology Segment

3. Superiority of Nanoparticle Based Drug Delivery over Traditional Drug Delivery

  • 3.1. Better Therapeutic Outcome than Conventional Drug Delivery Methods
  • 3.2. Role of Nanoparticles in Better Diagnosis of Cancer

4. Importance of Nanoparticle Drug Delivery in Cancer Therapy

  • 4.1. Wide Application of Nanoparticles in Cancer Therapy
  • 4.2. Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging & Therapy

5. Existing Techniques For Nanoparticle Drug Delivery

  • 5.1. Nanocrystals
  • 5.2. Liposomes
  • 5.3. Dendrimers
  • 5.4. Micelle Based Drug Delivery

6. Upcoming Nanoparticle Drug Delivery Techniques

  • 6.1. Polymeric Nanoparticles
  • 6.2. Metal based Nanoparticles (Gold, iron oxide)
  • 6.3. Fullerenes & Carbon Nanotube
  • 6.4. Quantum Dots Delivery

7. Global Nanoparticle Drug Market Overview

  • 7.1. Current Market Scenario
  • 7.2. Global Nanoparticle Drug Clinical Pipeline Overview

8. Price & Dosage Analysis of Commercially Available Nanoparticle Therapeutics

  • 8.1. Liposomal Doxorubicin
    • 8.1.1. Availability, Price & Mechanism of Action
    • 8.1.2. Dosage in Various Clinical Indications
    • 8.1.3. Liposomal Doxorubicin (Nanoparticle) v/s Traditional Doxorubicin - Comparative Analysis
  • 8.2. Amphotericin
    • 8.2.1. Availability, Price & Mechanism of Action
    • 8.2.2. Dosage by Indication
    • 8.2.3. Comparative Analysis- Conventional Amphotericin B v/s Nanoparticle Formulations
  • 8.3. Paclitaxel (Taxol, Onxal)
    • 8.3.1. Availability,Price & Mechanism of Action
    • 8.3.2. Dosage Analysis in Various Types of Cancer
    • 8.3.3. Paclitaxel v/s Abraxane(liposomal)
  • 8.4. Sirolimus (Rapamune)
    • 8.4.1. Availability,Price & Mechanism of Action
    • 8.4.2. Rapamune - Dosage Analysis
  • 8.5. Emend (Aprepitant Nanocrystal)
    • 8.5.1. Availability & Price
    • 8.5.2. Dosage Analysis
  • 8.6. Megace ES (Enhanced Stability)
    • 8.6.1. Availability, Price & Mechanism of Action
    • 8.6.2. Comparative Dosage Analyis - Megace v/s Megace ES
  • 8.7. Estradiol Topical Emulsion(Estrasorb)
  • 8.8. Other Nanoparticle Therapeutic Formulations
    • 8.8.1. Feraheme
    • 8.8.2. Triglide - Nanocrystal Version of Tricor

9. Nanoparticle Drug Delivery - Market Trend & Patent Distribution Analysis

  • 9.1. Patent Filing Status in Nanoparticle Drug Delivery
  • 9.2. Patent Distribution by Nanomaterial Type
  • 9.3. Patent Distribution by Stimulus
  • 9.4. Patent Distribution by Route of Administration & Forms of Drug Delivery

10. Driving Factors of Nanoparticle Drug Delivery Market

  • 10.1. Increasing Prevalence of Disease & the Need for Better Therapeutics
  • 10.2. Better Reliability & Safety than Conventional Therapeutics
  • 10.3. Advancement in Research & Development
  • 10.4. Promising Investment & Market Potential
  • 10.5. Rapid Advancement in Innovative and Superior Technology

11. Challenging Aspects of Nanoparticle Drug Delivery Segment

  • 11.1. Highly Expensive Technique & Nanoparticle Products
  • 11.2. Scientific & Technical Limitation Related to Nanoparticles Drug Delivery
  • 11.3. Regional Limitation & Low Market Penetrance
  • 11.4. Dominance of Conventional Drug Delivery Segment

12. Future Forecast & Market Analysis of Global Nanoparticle Drug Delivery Market

13. Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase

  • 13.1. Unknown
  • 13.2. Research
  • 13.3. Preclinical
  • 13.4. Clinical
  • 13.5. Phase-I
  • 13.6. Phase-I/II
  • 13.7. Phase-II
  • 13.8. Phase-II/III
  • 13.9. Phase-III
  • 13.10. Preregistration
  • 13.11. Registered

14. Marketed Nanoparticle Drug Clinical Insight by Company & Indication

  • 14.1. Rilpivirine (Edurant)
  • 14.2. Albumin-Bound Paclitaxel (Abraxane, Coraxane & Coroxane)
  • 14.3. Meloxicam (VIVLODEX)
  • 14.4. Ferumoxytol (Feraheme & Rienso)
  • 14.5. Paclitaxel Liposomal - Sun Pharma Advanced Research Company
  • 14.6. Fenofibrate (Lipanthyl & TriCor)
  • 14.7. Doxorubicin Liposomal (Caelyx & Doxil)
  • 14.8. Vincristine Liposomal (Marqibo)
  • 14.9. Fenofibrate (Triglide)
  • 14.10. Rexin-G
  • 14.11. Estradiol Topical (Estrasorb)
  • 14.12. Glycyrrhiza/Phosphatidylcholine (Phosphogliv)
  • 14.13. Paclitaxel Nanoparticle (Nanoxel)

15. Competitive Landscape

  • 15.1. Abraxis BioScience
  • 15.2. Access Pharmaceuticals
  • 15.3. Alnylam Pharmaceuticals
  • 15.4. Amgen
  • 15.5. Arrowhead Research
  • 15.6. BIND Therapeutics
  • 15.7. Cadila Healthcare
  • 15.8. Celegen Corporation
  • 15.9. Celsion Corporation
  • 15.10. Genzyme Corporation
  • 15.11. Merck
  • 15.12. NanoCarrier
  • 15.13. Nippon Kayaku
  • 15.14. Nanobiotix
  • 15.15. Novavax
  • 15.16. Pfizer
  • 15.17. Roche
  • 15.18. Samyang
  • 15.19. Sanofi
  • 15.20. Takeda Pharmaceutical

List of Figures

  • Figure 1-1: Evolution of Nanoparticle Drug Delivery
  • Figure 1-2: Different Drug Delivery Routes
  • Figure 1-3: Organic Nanoparticles Used in Drug Delivery
  • Figure 2-1: Limitations of Traditional Drug Delivery Therapy
  • Figure 2-2: Global- Drug Delivery Segmentation by Route of Administration (%), 2017
  • Figure 3-1: Superior Characteristic of Nanoparticle Drug Delivery
  • Figure 3-2: Application of Nanoparticles in Diagnosis
  • Figure 4-1: Inorganic Nanoparticles Used in Drug Delivery
  • Figure 4-2: Nanoparticle - Application in Imaging Techniques (%), 2017
  • Figure 5-1: Nanoparticles Market Segmentation by Types
  • Figure 5-2: Global- Nanoparticle Drug Delivery Segmentation by Technology (%), 2017
  • Figure 5-3: Liposome Drug Delivery in Action
  • Figure 5-4: Dendrimer Nanoparticle in Drug Delivery
  • Figure 6-1: Gold Nanoparticles in Drug Delivery
  • Figure 6-2: Fullerenes Being Used as Vectors (Carrying Agents)
  • Figure 6-3: Quantum Dots in Cancer Therapy
  • Figure 7-1: Global Nanoparticle Drug Market (US$ Billion), 2013-2017
  • Figure 7-2: Global - Nanoparticle Drug Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 7-3: Global Nanoparticle Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 8-1: Liposomal Doxorubicin - Availability by Concentration (ml)
  • Figure 8-2: Adriamycin - Price Analysis (US$/ml), 2018
  • Figure 8-3: Lipodox 50- Price Analysis (US$), 2018
  • Figure 8-4: Doxil- Dosage analysis for Ovarian Cancer (mg/m2)
  • Figure 8-5: Doxil - Dosage Analysis for Kaposi's sarcoma
  • Figure 8-6: Liposomal Doxorubicin - Dosage Analysis in Multiple Myeloma
  • Figure 8-7: Doxorubicin (Nanoparticle Variant)- Average Price Analysis (US$/ml), 2018
  • Figure 8-8: Comparative Dosage Analysis andndash; Traditional Doxorubicin v/s Liposomal Doxorubicin (mg/m2)
  • Figure 8-9: Doxorubicin- Comparative Price Analysis (US$/mg), 2018
  • Figure 8-10: Amphotericin B andndash; Availability by Concentration (mg/vial)
  • Figure 8-11: Conventional Amphotericin B- Dosage Analysis for Adult Fungal Infections (mg/kg)
  • Figure 8-12: Amphotericin B - Dosage Analysis in Pediatric Fungal Infection (mg/kg)
  • Figure 8-13: Liposomal Amphotericin B- Dosage Analysis by Indication (mg/kg)
  • Figure 8-14: Amphotericin B andndash; Comparative Daily Dosage Analysis by Formulation (mg/kg), 2018
  • Figure 8-15: Amphotericin B-Comparative Price Analysis by Formulation per Day (US$), 2018
  • Figure 8-16: Comparative Price Analysis andndash; Amphotericin B Nanoparticle Formulations (US$), 2018
  • Figure 8-17: Paclitaxel - Availability by Concentration (mg and ml)
  • Figure 8-18: Paclitaxel - Working Mechanism
  • Figure 8-19: Abraxane- Dosage Analysis by Cancer (mg/Cycle)
  • Figure 8-20: Paclitaxel Dosage Analysis by Cancer (mg/m2)
  • Figure 8-21: Price Analysis- Paclitaxel v/s Abraxane (US$), 2018
  • Figure 8-22: Paclitaxel v/s Abraxane andndash;Comparative Positive Response Rate (%)
  • Figure 8-23: Rapamune - Availability of Formulations (mg)
  • Figure 8-24: Rapamune - Cost Analysis by Formulation (US$), 2018
  • Figure 8-25: Rapamune - Dosage for Low Immune Risk Patients (mg)
  • Figure 8-26: Rapamune - Dosage for High Immunologic Risk (mg)
  • Figure 8-27: Emend - Price and Availability (US$), 2018
  • Figure 8-28: Emend - Dosage Analysis (mg/day)
  • Figure 8-29: Dosage Analysis - Megace v/s Megace ES (mg/day)
  • Figure 8-30: Megace v/s Megace ES - Comparative Price Analysis (US$), 2018
  • Figure 8-31: Estrasorb- Price Analysis (US$), 2018
  • Figure 8-32: Feraheme - Dosage Analysis (mg/ml)
  • Figure 8-33: Triglide - Availability by Concentration (mg)
  • Figure 8-34: Comparative Price Analysis -Triglide and Tricor (US$/Pack), 2018
  • Figure 9-1: Global- Patent Analysis by Cancer Types (Number), 2016
  • Figure 9-2: Global andndash; Nanoparticle Patent Filing Status by Region (Numbers), 2016
  • Figure 9-3: Global- Patent Distribution by Material Type (Numbers), 2016
  • Figure 9-4: Stimulus of Nanoparticles to Various Factors
  • Figure 9-5: Global- Patent Distribution by Stimulus (Numbers), 2016
  • Figure 10-1: Nanoparticle Drug Delivery - Driving Factors
  • Figure 10-2: Global - Nanoparticle Research in Cancer Segment (By number)
  • Figure 10-3: Magnetic Nanoparticle - Recent Advances in Drug Delivery
  • Figure 11-1: Nanoparticle Drug Delivery Market Challenges
  • Figure 12-1: Global - Nanoparticle Drug Deliver Dominance by Region (%), 2017
  • Figure 12-2: Global- Nanoparticle Drug Market (US$ Billion), 2018-2024
  • Figure 12-3: Global- Gold Nanoparticles Future Forecast (US$ Million), 2018 - 2024
  • Figure 12-4: Global - Investments in the Nanoparticle Drug Delivery Segment (US$ Billion), 2013-2017
  • Figure 15-1: Arrowhead Research Corporation Clinical Pipeline
  • Figure 15-2: NanoCarrier Clinical Pipeline

List of Tables

  • Table 5-1: List Of Commercially Available Nanocrystal Drugs and Their Indication
  • Table 5-2: Liposome Based Drugs - Current Status
  • Table 5-3: Current Market Status of Dendrimers
  • Table 6-4: Traditional Doxorubicin v/s Nanoparticle Doxorubicin
Back to Top